Search clinical trials for: Dapagliflozin 10 MG [Forxiga]

Total 1586 results

Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
Medical University of Vienna
Vienna Dialysis Center

Recruiting

SGLT2 Inhibition in Hemodialysis (DAPA-HD)

Diabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular Hypertrophy

Austria
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Australia, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Israel, Brazil, Finland, Greece, Mexico, United Kingdom and more
Hongchang Guo

Recruiting

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
National Heart Centre Singapore
Duke-NUS Medical School (Singapore)

Completed

Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment (DAPA-Shuttle1)

Heart Failure | Diabetes Mellitus

Singapore
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
University of Oxford
Oxford Brookes University; The Leona M. and Harry B. Helmsley Charitable Trust

Terminated

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia (DEPTH)

Diabetes Mellitus, Type 1

United Kingdom
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
Centre Hospitalier Universitaire Saint Pierre
AstraZeneca

Terminated

Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients (DAPAMICRO)

Diabetes Mellitus, Type 2

Belgium
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
George Clinical Pty Ltd
University Medical Center Groningen; Ground Zero Pharmaceuticals

Unknown

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Diabetes Mellitus, Type 2 | Impaired Renal Function

Canada
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Heart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Chang Gung Memorial Hospital

Active, not recruiting

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Catheter Ablation | Atrial Fibrillation Recurrent

Taiwan
AstraZeneca

Recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

Spain, Italy, China, Vietnam, United States, Brazil, Canada, Malaysia, Poland, Taiwan, Austria, Bulgaria, Chile, United Kingdom, Japan
Damanhour University
Menoufia University

Unknown

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Cardiomyopathies | Diabete Type 2 | Heart Failure With Reduced Ejection Fraction (HFrEF)
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III; University of Navarra; Fundación para la Investigación...

Unknown

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF (CARDIA-STIFF)

Diabetes Mellitus, Type 2 | Heart Failure With Preserved Ejection Fraction

Spain
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
LG Chem

Unknown

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

T2DM
University Medical Center Groningen
AstraZeneca; Dutch Kidney Foundation

Enrolling by invitation

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Heart Failure | Death | Kidney Disease, Chronic | Kidney Failure | Renal Transplant Failure

Netherlands, Germany, Australia
Oslo University Hospital
Karolinska University Hospital; Aarhus University Hospital; Erasmus Medical Center and other collaborators

Recruiting

DAPAgliflozin for Renal Protection in Heart Transplant Recipients (DAPARHT)

Kidney Failure | Heart Transplant Failure

Netherlands, Sweden, Denmark, Norway
Mads Ersbøll

Recruiting

Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH)

Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension

Denmark
The University of Texas Health Science Center at...
National Institute on Aging (NIA)

Completed

SGLT2 Inhibition in Older Obese Adults With Pre-diabetes (SGLT2i)

Aging

United States
Saint Luke's Health System
AstraZeneca; George Clinical Pty Ltd; Saint Luke's Hospital of Kansas City

Completed

Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)

COVID-19

United States, Brazil, Argentina, India, Canada, Mexico, United Kingdom
University of Campinas, Brazil
AstraZeneca

Completed

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (ADDENDA)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery Diseases

Brazil
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
Seoul National University Bundang Hospital

Recruiting

Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (Location-F)

Diabetes Type 2

Korea, Republic of
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 (MERCURI-2)

Acute Kidney Injury | Cardiac Surgery | Sodium-Glucose Transporter 2 Inhibitor

Netherlands
Region Örebro County
London School of Hygiene and Tropical Medicine; Odense University Hospital; Göteborg... and other collaborators

Recruiting

SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF (STENOTYPE)

Atrial Fibrillation | Chronic Coronary Syndrome

Denmark, Sweden, Czechia
October 6 University
University of Florida; Beni-Suef University; National Heart Institute, Egypt

Recruiting

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Heart Failure | Genetic Polymorphisms

United States
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa
Consano Clinical Research, LLC

Completed

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Diabetes Mellitus, Type 2

United States
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
4th Military Clinical Hospital with Polyclinic,...

Recruiting

CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL (PROTECTAA)

Heart Failure | Breast Cancer

Poland
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
AstraZeneca
Antaros Medical; Bioventure Hub; 43183 Mölndal; Sweden

Completed

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus (DERISC)

Type 2 Diabetes Mellitus

Finland
University of California, San Diego
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Type 1 Diabetes

United States
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
University Hospital Tuebingen

Terminated

Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment (DapaSaxaBBIT)

Type 2 Diabetes

Germany
Centro Universitario de Ciencias de la Salud, Mexico

Unknown

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD)

Chronic Kidney Disease

United States, Canada, Spain, United Kingdom, Denmark, Germany, Korea, Republic of, Brazil, Hungary, Mexico, Peru, Philippines, Vietnam, China, Japan, Argentina, Ukraine, Poland, Russian Federation, India, Sweden
University Hospital Tuebingen
AstraZeneca; German Federal Ministry of Education and Research; German Center...

Recruiting

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Renal Failure | PreDiabetes | Type2diabetes

Germany
Abramson Cancer Center of the University of Pennsylvania

Terminated

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia (UPCC04407)

Acute Myeloid Leukemia

United States

Search clinical trials for: Dapagliflozin 10 MG [Forxiga]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations